As potential alternatives to originator biologics, biosimilars may expand treatment options to meet the growing demand for biologic therapies¹

By providing potentially more cost-effective treatment options, biosimilars may allow for the reallocation of resources to other areas of patient care, while still delivering quality and effective results^1,2

There is the potential for improved outcomes as a result of earlier treatment with biologics³

• This is made possible by reducing costs, which may increase access to biosimilars compared with access to originator biologics³

As existing biologic medicines lose marketing exclusivity, biosimilar medicines may become increasingly important for managing difficult-to-treat diseases in a more cost-effective manner¹